Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791364631> ?p ?o ?g. }
- W2791364631 endingPage "2573" @default.
- W2791364631 startingPage "2559" @default.
- W2791364631 abstract "Abstract Purpose: Glioblastoma is the most aggressive primary brain tumor in adults with a median survival of 15–20 months. Numerous approaches and novel therapeutics for treating glioblastoma have been investigated in the setting of phase III clinical trials, including a recent analysis of the immune checkpoint inhibitor, nivolumab (anti-PD-1), which failed to improve recurrent glioblastoma patient survival. However, rather than abandoning immune checkpoint inhibitor treatment for glioblastoma, which has shown promise in other types of cancer, ongoing studies are currently evaluating this therapeutic class when combined with other agents. Experimental Design: Here, we investigated immunocompetent orthotopic mouse models of glioblastoma treated with the potent CNS-penetrating IDO1 enzyme inhibitor, BGB-5777, combined with anti-PD1 mAb, as well as radiotherapy, based on our recent observation that tumor-infiltrating T cells directly increase immunosuppressive IDO1 levels in human glioblastoma, the previously described reinvigoration of immune cell functions after PD-1 blockade, as well as the proinflammatory effects of radiation. Results: Our results demonstrate a durable survival benefit from this novel three-agent treatment, but not for any single- or dual-agent combination. Unexpectedly, treatment efficacy required IDO1 enzyme inhibition in non-glioblastoma cells, rather than tumor cells. Timing of effector T-cell infiltration, animal subject age, and usage of systemic chemotherapy, all directly impacted therapy-mediated survival benefit. Conclusions: These data highlight a novel and clinically relevant immunotherapeutic approach with associated mechanistic considerations that have formed the basis of a newly initiated phase I/II trial for glioblastoma patients. Clin Cancer Res; 24(11); 2559–73. ©2018 AACR." @default.
- W2791364631 created "2018-03-29" @default.
- W2791364631 creator A5000984321 @default.
- W2791364631 creator A5003799255 @default.
- W2791364631 creator A5016173245 @default.
- W2791364631 creator A5018742393 @default.
- W2791364631 creator A5019501470 @default.
- W2791364631 creator A5021366973 @default.
- W2791364631 creator A5022934767 @default.
- W2791364631 creator A5023585542 @default.
- W2791364631 creator A5023866306 @default.
- W2791364631 creator A5027761006 @default.
- W2791364631 creator A5032466182 @default.
- W2791364631 creator A5033080900 @default.
- W2791364631 creator A5041376388 @default.
- W2791364631 creator A5045295452 @default.
- W2791364631 creator A5050603971 @default.
- W2791364631 creator A5051335860 @default.
- W2791364631 creator A5051430312 @default.
- W2791364631 creator A5053052330 @default.
- W2791364631 creator A5063105699 @default.
- W2791364631 creator A5074800269 @default.
- W2791364631 creator A5082027834 @default.
- W2791364631 date "2018-05-31" @default.
- W2791364631 modified "2023-10-15" @default.
- W2791364631 title "IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma" @default.
- W2791364631 cites W1465620532 @default.
- W2791364631 cites W1569947394 @default.
- W2791364631 cites W1815157104 @default.
- W2791364631 cites W1931474344 @default.
- W2791364631 cites W1986710534 @default.
- W2791364631 cites W1991243877 @default.
- W2791364631 cites W2007316487 @default.
- W2791364631 cites W2020812892 @default.
- W2791364631 cites W2026429388 @default.
- W2791364631 cites W2032166347 @default.
- W2791364631 cites W2044184535 @default.
- W2791364631 cites W2045472160 @default.
- W2791364631 cites W2052727153 @default.
- W2791364631 cites W2053393698 @default.
- W2791364631 cites W2054995801 @default.
- W2791364631 cites W2080635576 @default.
- W2791364631 cites W2096287682 @default.
- W2791364631 cites W2097049582 @default.
- W2791364631 cites W2107277218 @default.
- W2791364631 cites W2112820219 @default.
- W2791364631 cites W2143565660 @default.
- W2791364631 cites W2143772132 @default.
- W2791364631 cites W2149398709 @default.
- W2791364631 cites W2158681922 @default.
- W2791364631 cites W2159822434 @default.
- W2791364631 cites W2165871546 @default.
- W2791364631 cites W2166662937 @default.
- W2791364631 cites W2190672185 @default.
- W2791364631 cites W2192080449 @default.
- W2791364631 cites W2222086386 @default.
- W2791364631 cites W2283665483 @default.
- W2791364631 cites W2418354692 @default.
- W2791364631 cites W2506204039 @default.
- W2791364631 cites W2559827530 @default.
- W2791364631 cites W2566833162 @default.
- W2791364631 cites W2572174216 @default.
- W2791364631 cites W2584371626 @default.
- W2791364631 cites W2589009574 @default.
- W2791364631 cites W2739812295 @default.
- W2791364631 cites W2741270291 @default.
- W2791364631 cites W2767648791 @default.
- W2791364631 cites W2778283729 @default.
- W2791364631 cites W2806431043 @default.
- W2791364631 doi "https://doi.org/10.1158/1078-0432.ccr-17-3573" @default.
- W2791364631 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5984675" @default.
- W2791364631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29500275" @default.
- W2791364631 hasPublicationYear "2018" @default.
- W2791364631 type Work @default.
- W2791364631 sameAs 2791364631 @default.
- W2791364631 citedByCount "134" @default.
- W2791364631 countsByYear W27913646312018 @default.
- W2791364631 countsByYear W27913646312019 @default.
- W2791364631 countsByYear W27913646312020 @default.
- W2791364631 countsByYear W27913646312021 @default.
- W2791364631 countsByYear W27913646312022 @default.
- W2791364631 countsByYear W27913646312023 @default.
- W2791364631 crossrefType "journal-article" @default.
- W2791364631 hasAuthorship W2791364631A5000984321 @default.
- W2791364631 hasAuthorship W2791364631A5003799255 @default.
- W2791364631 hasAuthorship W2791364631A5016173245 @default.
- W2791364631 hasAuthorship W2791364631A5018742393 @default.
- W2791364631 hasAuthorship W2791364631A5019501470 @default.
- W2791364631 hasAuthorship W2791364631A5021366973 @default.
- W2791364631 hasAuthorship W2791364631A5022934767 @default.
- W2791364631 hasAuthorship W2791364631A5023585542 @default.
- W2791364631 hasAuthorship W2791364631A5023866306 @default.
- W2791364631 hasAuthorship W2791364631A5027761006 @default.
- W2791364631 hasAuthorship W2791364631A5032466182 @default.
- W2791364631 hasAuthorship W2791364631A5033080900 @default.
- W2791364631 hasAuthorship W2791364631A5041376388 @default.
- W2791364631 hasAuthorship W2791364631A5045295452 @default.
- W2791364631 hasAuthorship W2791364631A5050603971 @default.